Advaxis Inc. Finds Big Injection Of Bullish Momentum Following Latest Announcement
December 15th marked the day that the FDA cleared Advaxis (ADXS) for its potential “liftoff”. Specifically, this biotech company’s application for an Investigational New Drug was clear to begin a Phase 1/2 trial of ADXS-HPV to treat HPV-associated cervical cancer and HPV-associated head and neck cancer. According to Company management, Advaxis expects to begin patient enrollment in the trial in early 2015.
The real uptrend for this biotech stock began in late November following the announcement that the Company had submitted the IND application. To date, the stock has seen a jump in price of more than 230 percent in less than 2 months.
Zack’s research reports: “Advaxis has developed a proprietary platform technology called Lm-LLO, which utilizes live attenuated Listeria monocytogenes bacteria to initiate an immune response to selected cancer associated antigens. It is the only immunotherapy known to generate cancer fighting T-cells against a specific tumor antigen (HER2, HPV, etc.) while neutralizing T regulatory cells and myeloid-derived suppressor cells which protect tumors from immune attack. In a recent Phase II trial, the combination of ADXS-HPV and chemotherapy demonstrated safety and improved survival. The combinational use of Advaxis’s novel platform with checkpoint inhibitors such as MEDI4736 could be a significant value driver for the Company. Just last week, the Company announced the initiation of a Phase I/II trial with Merck’s FDA approved PD-1 anti-body, pembrolizumab, for the treatment of prostate cancer.”